10-Q: Vitro BioPharma Reports Reduced Quarterly Loss Amidst Continued Going Concern Doubts and New Capital Raises

Vitro BioPharma, Inc. reported a significant reduction in net loss for the three and six months ended April 30, 2025, while acknowledging substantial doubt about its ability to continue as a going concern and actively pursuing new capital.

Summary

• Vitro BioPharma, Inc. incurred a net loss of $1,478,786 for the three months ended April 30, 2025, a 53% decrease from the $3,118,919 loss in the same period last year.
• For the six months ended April 30, 2025, the net loss was $4,313,448, a 44% decrease from the $7,688,105 loss in the prior year period.
• Total revenue for the three months ended April 30, 2025, decreased by 11% to $511,584, primarily due to a 22% decrease in research and development product sales and a 3% decrease in AlloRx Stem Cells sales to foreign third-party clinics.
• Total revenue for the six months ended April 30, 2025, decreased by 4% to $961,458.
• Gross profit percentage decreased to 74% for the three months and 76% for the six months ended April 30, 2025, compared to 84% and 82% respectively in the prior year, due to higher production costs.
• Selling, General and Administrative (SG&A) expenses decreased by 4% for the three months and 9% for the six months ended April 30, 2025, primarily due to reductions in consulting and legal fees.
• Research and Development (R&D) expenses increased by 59% for the three months ended April 30, 2025, to $222,431, as the Company continues to identify additional indications for its therapies.
• Interest expense saw a substantial reduction, decreasing by 79% for the six months ended April 30, 2025, to $499,653, mainly due to debt discount accretion reductions related to the 2024 Senior Secured Notes.
• The Company recognized a gain on forgiveness of debt of $343,938 from the renegotiation and full payment of the 2021 Series Convertible Notes Payable.
• A loss on extinguishment of debt of $1,235,000 was recorded due to the extension and renegotiation of the July Series 2024 note.
• The Company reported a working capital deficit of approximately $13.3 million as of April 30, 2025, an increase of $4.2 million from October 31, 2024.
• Cash balance decreased to $198,075 as of April 30, 2025, from $571,360 at October 31, 2024.
• The Company issued $6,687,500 in principal amount of 2025 Series Senior Secured Convertible Notes for net proceeds of $5,350,000 during the six months ended April 30, 2025.
• Subsequent to the reporting period, the Company received an additional $325,000 cash advance under the 2025 Senior Secured Notes terms and $350,000 in A-1 Preferred Stock investments, part of a larger $15,000,000 offering.
• The Company's accumulated deficit reached $42.3 million as of April 30, 2025.

Sentiment

Score: 3

Explanation: The sentiment is largely negative due to the explicit 'going concern' warning, significant accumulated deficit, and continued working capital deficit. While there's a positive trend in reduced net losses and successful capital raises, these are primarily to sustain operations and fund future development rather than indicating immediate profitability or financial stability. The company remains highly dependent on future financing, which carries substantial risks.

Positives

• Net loss significantly decreased by 53% for the three months and 44% for the six months ended April 30, 2025, compared to the prior year periods.
• Interest expense saw a substantial reduction of 79% for the six months ended April 30, 2025, primarily due to debt discount accretion reductions.
• The Company successfully renegotiated and fully paid off the 2021 Series Convertible Notes Payable, resulting in a gain on forgiveness of debt of $343,938.
• New capital was raised through the issuance of 2025 Series Senior Secured Convertible Notes ($5.35 million net proceeds) and initial investments in A-1 Preferred Stock ($450,000 subsequent to period end), indicating continued investor interest.
• The Company is actively pursuing clinical trials for AlloRx Stem Cell therapy in PTHS and Long COVID, demonstrating progress in its core regenerative medicine business.

Negatives

• The Company continues to incur significant net losses, with an accumulated deficit of $42.3 million as of April 30, 2025.
• A substantial doubt exists about the Company's ability to continue as a going concern within one year.
• Working capital deficit increased to approximately $13.3 million as of April 30, 2025, from $9.1 million at October 31, 2024.
• Total revenue decreased by 11% for the three months and 4% for the six months ended April 30, 2025, compared to the prior year periods.
• Gross profit percentages declined due to higher costs of production.
• A loss on extinguishment of debt of $1,235,000 was recorded due to the renegotiation of the July Series 2024 note.
• Cash balance significantly decreased to $198,075 from $571,360 in six months.
• Sales of Fitore products are expected to be limited to remaining inventory, with no anticipated additional manufacturing, indicating a reduction in this business line.

Risks

• Substantial doubt about the Company's ability to continue as a going concern within one year due to incurred net losses and inadequate working capital.
• Dependence on raising additional capital through public/private equity or debt financings, or strategic alliances, with no assurance of success.
• Potential for dilution of existing stockholders' ownership interest if additional capital is raised through equity or convertible debt securities.
• Possible imposition of debt covenants, increased fixed payment obligations, or other restrictions from future financings.
• Risk of relinquishing valuable rights to technologies, future revenue streams, research programs, or product candidates if funds are raised through third-party collaborations.
• Uncertainty regarding the nature, timing, or costs required to complete the remaining development of product candidates and obtain regulatory approval.
• Fluctuations in sales volumes of research products (CAFs and native fibroblasts) due to their purchase order basis and lack of minimum purchase obligations.
• Expected increases in Selling, General and Administrative (SG&A) expenses due to increased headcount and costs associated with being a public company.
• Expected significant increases in Research and Development (R&D) expenses upon commencement of clinical trials.
• Potential for material write-downs of intangible assets if market conditions or management estimates differ from current expectations.
• Risk of litigation or regulatory matters, although none are currently pending or threatened.
• The securities offered in private placements are illiquid, with no public market, and subject to restrictions on transferability.
• The Company's ability to commence planned clinical trials for AlloRx Stem Cell therapy (PTHS and Long COVID) is pending receipt of sufficient working capital, posing a delay risk.

Future Outlook

Vitro BioPharma expects to continue reporting losses until it can improve the operations of its acquired subsidiaries or commercialize product candidates to offset operating and interest expenses. The Company anticipates an increase in AlloRx Stem Cell sales internationally and expects SG&A and R&D expenses to rise as it increases headcount and advances preclinical and clinical development programs. The commencement of planned Phase 1/2a clinical trials for PTHS and Long COVID is contingent on securing substantial additional capital, estimated at $4 million to $6 million.

Management Comments

• "We expect to continue reporting losses until such time, if ever, we can improve the operation of our newly acquired subsidiaries and/or commercialize one or more of our product candidates and generate sales sufficient to offset our operating costs and expenses and interest expenses."
• "We expect AlloRx Stem Cell sales internationally to increase over the next year as these products expand into additional foreign third-party clinics and medical centers and our current foreign third-party clinics and medical center customers increase their total monthly patients as international travel continues to pick back up."
• "We expect that our SG&A expenses will increase in the future as we expect to increase our headcount to support increased research and development activities relating to our clinical programs."
• "We expect our research and development expenses to increase significantly for the foreseeable future when we commence clinical trials and advance the pre-clinical and clinical development of our programs, including the conduct of our planned clinical trials."
• "Our current cash position is not sufficient to support our daily operations for the next 12 months."
• "Our ability to continue as a going concern is dependent upon our ability to raise additional funds through debt or equity financings and our ability to further implement our business plan and generate additional revenue."
• "There is no assurance that these initiatives will yield sufficient capital to maintain the Company's operations. There is no assurance that the ongoing capital raising efforts will be successful."
• "Should management fail to successfully raise additional capital and/or fully implement its strategic initiatives, it may be compelled to curtail part or all of its ongoing operations."
• "We do not anticipate commencing any clinical trials of our AlloRx Stem Cell therapy unless and until we receive substantial additional capital, as costs are estimated to be $4 million to $6 million to commence our contemplated Phase 1/2a clinical trials for PTHS and Long COVID, depending on whether we commence one or both trials."

Industry Context

Vitro BioPharma operates in the highly capital-intensive biotechnology sector, specifically focusing on regenerative medicine for autoimmune and inflammatory disorders, alongside research services and cosmeceuticals. The Company's strategy to develop novel cellular therapeutic candidates aligns with broader industry trends towards advanced therapies. However, its reliance on external financing for clinical trials and ongoing operations is typical for early-stage biotech firms, but the explicit 'going concern' warning highlights a more precarious financial position compared to more established players. The continued pursuit of clinical trials for conditions like Long COVID and PTHS reflects the industry's focus on addressing unmet medical needs, but also the inherent high risks and significant funding requirements.

Related Party Transactions

• Sales to Dr. Jack Zamora (former CEO and 30% stockholder) accounted for $2,250 (3 months) and $18,000 (6 months) of product sales for the period ended April 30, 2025.
• As of April 30, 2025, Dr. Zamora owed the Company $2,250 in accounts receivable.
• The Company leases office and lab space from an entity controlled by the spouse of its Chief Science Officer at $5,645 per month, with the lease running through June 2030.
• As of April 30, 2025, the Company owed its CEO $22,610 in travel expense reimbursements.
• The 2021 Series Convertible Notes Payable, a related party debt, was renegotiated to $225,000 (non-interest bearing) and fully paid on April 30, 2025, resulting in a gain on forgiveness of debt of $343,938.
• John Evans, a greater than 5% stockholder and former CFO, provides advisory services under a consulting agreement for $200,000 per year (increasing to $250,000 upon $10M financing), which terminates on December 1, 2025.

Stakeholder Impact

• **Shareholders:** Face significant dilution risk from ongoing and future equity and convertible debt financings. The 'going concern' warning indicates a high risk of capital loss. However, the reduction in net loss and continued R&D efforts could offer long-term potential if the company achieves profitability and successful commercialization.
• **Employees:** The Company expects to increase headcount to support R&D and public company operations, which could lead to job growth. However, the 'going concern' risk implies potential instability if capital is not secured.
• **Customers:** Continued product sales, including AlloRx Stem Cells, indicate ongoing service. The Company's focus on expanding international sales suggests potential for broader customer reach.
• **Creditors:** The Company has substantial outstanding debt, though some has been renegotiated and paid off. The 'going concern' warning indicates elevated risk for remaining creditors, but new secured notes provide some collateral.
• **Suppliers:** The Company's financial health and reliance on external funding could impact its ability to meet obligations to suppliers, though no specific issues were noted.

Next Steps

• Raise additional capital through public and/or private offerings of equity securities or additional debt instruments.
• Implement initiatives to increase revenue generation through diversified offerings of products and services related to stem cell technology and analytical capabilities.
• Pursue various strategic alliances for growth and development.
• Commence Phase 1/2a clinical trials for AlloRx Stem Cell therapy in PTHS and Long COVID, pending sufficient working capital.
• Increase headcount to support increased research and development activities and public company operations.
• Expand the intellectual property portfolio.
• Seek regulatory approval for product candidates that successfully complete clinical development.
• Expand manufacturing capabilities, potentially adding clean rooms (estimated cost $0.3M-$0.5M).

Key Dates

Recommendation

Keywords

Biopharma, Stem Cell Therapy, Regenerative Medicine, SEC Filing, 10-Q, Financial Results, Net Loss, Revenue, Going Concern, Capital Raise, Convertible Notes, Clinical Trials, AlloRx Stem Cells, InfiniVive, Fitore, Debt Extinguishment, Working Capital Deficit, Research and Development, Corporate Governance, Risk Factors